ParkinsonCanadaV1, France, Analysis, bibRecord, 000073

Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.

Identifieur interne : 000073 ( France/Analysis ); précédent : 000072; suivant : 000074

Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.

Auteurs : Olivier Rascol [France] ; Susan Fox [Canada] ; Fabrizio Gasparini [Suisse] ; Christopher Kenney [États-Unis] ; Thérèse Di Paolo [Canada] ; Baltazar Gomez-Mancilla [Canada]

Source :

Parkinsonism & related disorders [ 1873-5126 ] ; 2014.

RBID : pubmed:24951359

English descriptors

KwdEn :
- Animals, Antiparkinson Agents (adverse effects), Disease Models, Animal, Dyskinesias (drug therapy), Humans, Levodopa (adverse effects), Parkinson Disease (drug therapy), Receptor, Metabotropic Glutamate 5 (antagonists & inhibitors).
MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , antagonists & inhibitors : Receptor, Metabotropic Glutamate 5.
- drug therapy : Dyskinesias, Parkinson Disease.
- Animals, Disease Models, Animal, Humans.

Abstract

Modulation of metabotropic glutamate receptors may be a novel therapeutic approach to manage L-Dopa-induced dyskinesias in patients with Parkinson's disease. This article reviews the rationale for use of metabotropic glutamate 5-receptor antagonists in experimental and clinical L-Dopa-induced dyskinesias.

DOI: 10.1016/j.parkreldis.2014.05.003
PubMed: 24951359

Affiliations:

Links to Exploration step

pubmed:24951359

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.</title>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="3"><nlm:affiliation>Clinical Investigation Center CIC9302 and Department of Neurosciences and Clinical Pharmacology, INSERM UMR825, Toulouse University Hospital and University of Toulouse III, Toulouse, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Investigation Center CIC9302 and Department of Neurosciences and Clinical Pharmacology, INSERM UMR825, Toulouse University Hospital and University of Toulouse III, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fox, Susan" sort="Fox, Susan" uniqKey="Fox S" first="Susan" last="Fox">Susan Fox</name>
<affiliation wicri:level="4"><nlm:affiliation>Movement Disorder Clinic, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorder Clinic, University of Toronto, Toronto Western Hospital, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gasparini, Fabrizio" sort="Gasparini, Fabrizio" uniqKey="Gasparini F" first="Fabrizio" last="Gasparini">Fabrizio Gasparini</name>
<affiliation wicri:level="1"><nlm:affiliation>Novartis Institutes for Biomedical Research, Basel, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Novartis Institutes for Biomedical Research, Basel</wicri:regionArea>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kenney, Christopher" sort="Kenney, Christopher" uniqKey="Kenney C" first="Christopher" last="Kenney">Christopher Kenney</name>
<affiliation wicri:level="2"><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name>
<affiliation wicri:level="1"><nlm:affiliation>Neuroscience Research Unit, Centre Hospitalier Universitaire de Québec, Québec, Canada; Faculty of Pharmacy, Laval University, Québec, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Neuroscience Research Unit, Centre Hospitalier Universitaire de Québec, Québec, Canada; Faculty of Pharmacy, Laval University, Québec</wicri:regionArea>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gomez Mancilla, Baltazar" sort="Gomez Mancilla, Baltazar" uniqKey="Gomez Mancilla B" first="Baltazar" last="Gomez-Mancilla">Baltazar Gomez-Mancilla</name>
<affiliation wicri:level="4"><nlm:affiliation>Novartis Institutes for Biomedical Research, Basel, Switzerland; Department of Neurology and Neurosurgery, McGill University, Montreal, Québec, Canada. Electronic address: baltazar.gomezmancilla@novartis.com.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Novartis Institutes for Biomedical Research, Basel, Switzerland; Department of Neurology and Neurosurgery, McGill University, Montreal, Québec</wicri:regionArea>
<orgName type="university">Université McGill</orgName>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24951359</idno>
<idno type="pmid">24951359</idno>
<idno type="doi">10.1016/j.parkreldis.2014.05.003</idno>
<idno type="wicri:Area/PubMed/Corpus">000691</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000691</idno>
<idno type="wicri:Area/PubMed/Curation">000691</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000691</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000691</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000691</idno>
<idno type="wicri:Area/Ncbi/Merge">001799</idno>
<idno type="wicri:Area/Ncbi/Curation">001799</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001799</idno>
<idno type="wicri:Area/Main/Merge">000872</idno>
<idno type="wicri:Area/Main/Curation">000871</idno>
<idno type="wicri:Area/Main/Exploration">000871</idno>
<idno type="wicri:Area/France/Extraction">000073</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.</title>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="3"><nlm:affiliation>Clinical Investigation Center CIC9302 and Department of Neurosciences and Clinical Pharmacology, INSERM UMR825, Toulouse University Hospital and University of Toulouse III, Toulouse, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Investigation Center CIC9302 and Department of Neurosciences and Clinical Pharmacology, INSERM UMR825, Toulouse University Hospital and University of Toulouse III, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fox, Susan" sort="Fox, Susan" uniqKey="Fox S" first="Susan" last="Fox">Susan Fox</name>
<affiliation wicri:level="4"><nlm:affiliation>Movement Disorder Clinic, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorder Clinic, University of Toronto, Toronto Western Hospital, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gasparini, Fabrizio" sort="Gasparini, Fabrizio" uniqKey="Gasparini F" first="Fabrizio" last="Gasparini">Fabrizio Gasparini</name>
<affiliation wicri:level="1"><nlm:affiliation>Novartis Institutes for Biomedical Research, Basel, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Novartis Institutes for Biomedical Research, Basel</wicri:regionArea>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kenney, Christopher" sort="Kenney, Christopher" uniqKey="Kenney C" first="Christopher" last="Kenney">Christopher Kenney</name>
<affiliation wicri:level="2"><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name>
<affiliation wicri:level="1"><nlm:affiliation>Neuroscience Research Unit, Centre Hospitalier Universitaire de Québec, Québec, Canada; Faculty of Pharmacy, Laval University, Québec, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Neuroscience Research Unit, Centre Hospitalier Universitaire de Québec, Québec, Canada; Faculty of Pharmacy, Laval University, Québec</wicri:regionArea>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gomez Mancilla, Baltazar" sort="Gomez Mancilla, Baltazar" uniqKey="Gomez Mancilla B" first="Baltazar" last="Gomez-Mancilla">Baltazar Gomez-Mancilla</name>
<affiliation wicri:level="4"><nlm:affiliation>Novartis Institutes for Biomedical Research, Basel, Switzerland; Department of Neurology and Neurosurgery, McGill University, Montreal, Québec, Canada. Electronic address: baltazar.gomezmancilla@novartis.com.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Novartis Institutes for Biomedical Research, Basel, Switzerland; Department of Neurology and Neurosurgery, McGill University, Montreal, Québec</wicri:regionArea>
<orgName type="university">Université McGill</orgName>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Parkinsonism & related disorders</title>
<idno type="eISSN">1873-5126</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Disease Models, Animal</term>
<term>Dyskinesias (drug therapy)</term>
<term>Humans</term>
<term>Levodopa (adverse effects)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Receptor, Metabotropic Glutamate 5 (antagonists & inhibitors)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Receptor, Metabotropic Glutamate 5</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesias</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Modulation of metabotropic glutamate receptors may be a novel therapeutic approach to manage L-Dopa-induced dyskinesias in patients with Parkinson's disease. This article reviews the rationale for use of metabotropic glutamate 5-receptor antagonists in experimental and clinical L-Dopa-induced dyskinesias.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
<li>France</li>
<li>Suisse</li>
<li>États-Unis</li>
</country>
<region><li>Midi-Pyrénées</li>
<li>New Jersey</li>
<li>Occitanie (région administrative)</li>
<li>Ontario</li>
<li>Québec</li>
</region>
<settlement><li>Montréal</li>
<li>Toronto</li>
<li>Toulouse</li>
</settlement>
<orgName><li>Université McGill</li>
<li>Université de Toronto</li>
</orgName>
</list>
<tree><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
</region>
</country>
<country name="Canada"><region name="Ontario"><name sortKey="Fox, Susan" sort="Fox, Susan" uniqKey="Fox S" first="Susan" last="Fox">Susan Fox</name>
</region>
<name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name>
<name sortKey="Gomez Mancilla, Baltazar" sort="Gomez Mancilla, Baltazar" uniqKey="Gomez Mancilla B" first="Baltazar" last="Gomez-Mancilla">Baltazar Gomez-Mancilla</name>
</country>
<country name="Suisse"><noRegion><name sortKey="Gasparini, Fabrizio" sort="Gasparini, Fabrizio" uniqKey="Gasparini F" first="Fabrizio" last="Gasparini">Fabrizio Gasparini</name>
</noRegion>
</country>
<country name="États-Unis"><region name="New Jersey"><name sortKey="Kenney, Christopher" sort="Kenney, Christopher" uniqKey="Kenney C" first="Christopher" last="Kenney">Christopher Kenney</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000073 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000073 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     pubmed:24951359
   |texte=   Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/RBID.i   -Sk "pubmed:24951359" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.

Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.